• Hydrocortisone in Translational Oncology: From Barrier Defen

  2026-07-04

  Explore the role of hydrocortisone, a key glucocorticoid hormone, in translational oncology research. This article uncovers how hydrocortisone bridges inflammation models, barrier function, and cancer stemness, offering unique assay insights and evidence-based protocols.

• Metformin Hydrochloride: Mechanistic Insights and Protocols

  2026-07-03

  Explore the multifaceted mechanisms of Metformin Hydrochloride (Metformin HCl) in metabolic and bone research. This article uniquely integrates molecular pathways, translational insights, and detailed experimental parameters for researchers investigating glucose metabolism and heterotopic ossification.

• Ivermectin’s Role in Next-Gen Anti-Parasitic and Tumor Micro

  2026-07-03

  Explore how Ivermectin, a broad-spectrum anti-parasitic agent, is transforming both parasitology research and experimental oncology. This article delivers a deeper, protocol-driven analysis, highlighting unique assay considerations and translational insights not found in standard reviews.

• Arachidonic Acid: Optimizing Immunity and Inflammation Assay

  2026-07-02

  Arachidonic Acid (SKU C4223) empowers bench scientists to finely tune models of inflammation and immune modulation, with recent evidence linking dietary supplementation to enhanced vaccine antibody responses in both mice and humans. This guide translates cutting-edge findings into protocol enhancements and troubleshooting tips for eicosanoid, cyclooxygenase, and immune cell workflows.

• Translating Mouse IL-12 mRNA Into Next-Gen Immunotherapy Too

  2026-07-02

  This article explores how mechanistically engineered mRNA—specifically EZ Cap™ Mouse IL-12 mRNA (m1Ψ)—is reshaping translational immunotherapy research. We connect molecular insights, delivery innovations, and practical protocol guidance, drawing from recent advances in extrahepatic targeting and virus-mimetic nanoparticles. By integrating evidence from primary literature and comparative resources, this piece offers strategic advice for researchers seeking to unlock the full potential of cytokine mRNA in precision immune modulation.

• Optimizing Assays With Cell Counting Kit-8 (CCK-8) Plus

  2026-07-01

  Cell Counting Kit-8 (CCK-8) Plus provides a sensitive, rapid, and reproducible method for quantifying cell proliferation and cytotoxicity, especially where conventional tetrazolium salt assays fall short in sensitivity or linearity. It is ideal for routine cell viability, drug screening, and cytotoxicity assays, but should not be used where metabolic readouts are confounded by interfering compounds or non-reducing cell types.

• Gap26 Connexin 43 Mimetic Peptide: Optimizing Gap Junction R

  2026-07-01

  Gap26, a selective connexin 43 mimetic peptide, empowers researchers to dissect intercellular signaling with unmatched precision—enabling robust studies of calcium signaling, ATP release, and mitochondrial transfer. See how advanced workflows and troubleshooting strategies using Gap26 drive reproducibility and translational relevance in cardiovascular, neuroprotection, and inflammation research.

• Deferasirox Fe3+ chelate (A3355): Reliable Iron Chelation in

  2026-06-30

  This article guides biomedical researchers through real-world scenarios where Deferasirox Fe3+ chelate (SKU A3355) ensures reproducible, sensitive, and workflow-compatible solutions in cell viability and iron metabolism assays. By addressing practical challenges and integrating recent peer-reviewed evidence, we illustrate why APExBIO’s high-purity, DMSO-soluble Deferasirox Fe3+ chelate is a dependable choice for iron overload treatment research and beta-thalassemia models.

• Dual Recombinase Tracing Disproves Postnatal Neo-oogenesis i

  2026-06-30

  A recent study by Xie, Zhou, and Zheng introduces a dual recombinase-mediated genetic tracing system to rigorously test the existence of postnatal neo-oogenesis in mice. Their work provides compelling evidence that new oocyte generation does not occur after birth, even following ovarian injury, refining the foundational understanding and experimental modeling in mammalian reproductive biology.

• ER-Targeted Peptide Self-Assembly for Cancer Cell Fate Modul

  2026-06-29

  This article examines a study that advances enzyme-instructed self-assembly (EISA) by engineering endoplasmic reticulum (ER)-targeting peptides for selective modulation of cancer cell fate. The approach leverages elevated alkaline phosphatase (ALP) in cancer cells to induce ER-localized assemblies, triggering ER stress and enhancing cell death pathways, with implications for more efficient, organelle-targeted cancer therapies.

• LY2228820: Selective p38 MAP Kinase Inhibitor for Research

  2026-06-29

  LY2228820 is a selective, ATP-competitive p38 MAP kinase inhibitor with nanomolar potency for p38α/β isoforms. It enables precise modulation of inflammation and cell proliferation pathways in anti-inflammatory and cancer research, as demonstrated by multiomics and translational studies.

• Tomivosertib Suppresses Ectopic Activity in Human DRG Neuron

  2026-06-28

  The referenced study provides the first direct evidence that tomivosertib, a MNK inhibitor, rapidly and reversibly reduces spontaneous ectopic activity in human dorsal root ganglion neurons from patients with radiculopathy. These findings highlight a potential translational pathway for targeting neuropathic pain at its peripheral neuronal source.

• Unraveling sEH/Nrf2 Mechanisms: BPN-19186 in Translational R

  2026-06-27

  (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) is reshaping biochemical research on osteoclastogenesis and redox signaling. This article bridges mechanistic insight, protocol recommendations, and strategic guidance for translational researchers seeking to harness APExBIO's high-purity inhibitor in signaling pathway and enzyme inhibition studies, with a focus on osteoporosis and beyond.

• Auranofin and the Future of Redox-Driven Cancer Research

  2026-06-26

  This article explores how Auranofin, a gold-based thioredoxin reductase inhibitor, is redefining translational oncology by targeting redox homeostasis, apoptosis, and radiosensitivity. Going beyond conventional product narratives, we integrate mechanistic insights, recent literature, and actionable guidance—positioning Auranofin as a strategic tool for researchers tackling metabolic reprogramming and therapy resistance in hepatocellular carcinoma and other aggressive cancers.

• ECL Western Blotting Substrate: Protocol Guidance and Best U

  2026-06-26

  ECL Western Blotting Substrate (SKU K2187) addresses the need for sensitive, nonradioactive detection of horseradish peroxidase (HRP) in chemiluminescent Western blot assays. It should be used exclusively for HRP-based immunoblotting and is not suitable for fluorescent or radioisotopic detection protocols.

445 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page